New article 19 March 2024

In the last ten years, the advent of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has been shown in several landmark trials to have striking benefits on diabetic, cardiovascular and renal outcomes. This has led to the rapid adoption of these agents in many treatment guidelines. In renal medicine especially, SGLT2is represent a paradigm shift in the preventative approach to chronic kidney disease (CKD).¹ 

In the last ten years, the advent of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has been shown in several landmark trials to have striking benefits on diabetic, cardiovascular and renal outcomes. This has led to the rapid adoption of these agents in many treatment guidelines. In renal medicine especially, SGLT2is represent a paradigm shift in the preventative approach to chronic kidney disease (CKD).[1]